BioKier completed a 12-week clinical study of BKR-017 in type 2 diabetes patients

Despite significant delays related to COVID-19, in late 2022 BioKier completed a 12-week clinical study (Study Number CL-501) conducted at three investigational sites: Duke University, Kannapolis NC; Duke University, Pickett Road, NC; and Pennington Biomedical Research, Baton Rouge, LA. ClinicalTrials.gov Identifier: NCT04279444

The release as fetched from its publisher. biokier.com ↗